Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the shares of Allergy Therapeutics plc. On August 4, 2023, Panmure Gordon purchased 0.1p ordinary shares of Allergy Therapeutics plc. The total number of securities purchased was 0, with no price per unit paid. Panmure Gordon also sold 215,712 0.1p ordinary shares of Allergy Therapeutics plc, with the highest price per unit received at 0.0357 and the lowest price per unit received at 0.0345.

No cash-settled derivative transactions or stock-settled derivative transactions were reported. There were no other dealings, such as subscribing for new securities, reported by Panmure Gordon.

No indemnity or option arrangements, agreements, or understandings relating to relevant securities were disclosed by Panmure Gordon. Similarly, no agreements, arrangements, or understandings relating to options or derivatives were reported.

The disclosure was made on August 7, 2023, and the contact person for further information is Lauren Riley at Panmure Gordon, with a telephone number of 020 7886 2963.